Enaleni (soon to be renamed Cipla Medpro South Africa Ltd) is South Africa’s sixth largest and fastest growing pharmaceutical company through its subsidiary Cipla Medpro, which has access to one of the best pipelines in the world through a 20 year supply agreement with Cipla India, and commands a substantial share of the local chronic medicines market targeting inter alia, the respiratory, cardiovascular, ARV and diabetes markets.
The group’s 4 000m2 manufacturing facility in Durban, KwaZulu-Natal is currently under going a R175 million upgrade to international PIC/S compliance and this is due for completion in the second half of 2008.
Credit Cuisse produces a report comparing biotech, biopharma, life sciences and generics by its analysts. In the latest edition it includes Enaleni Pharmaceuticals (ENL), Adcock Ingram (AIP) and Aspen Pharmacare (APN).
Enaleni appears to be completely undervalued! There are huge prospects in the company following the completion and opening of the upgraded manufacturing facility.
The current price sits at around R2.30 and the target price is around R3.84. That’s a 67% upside with a 12 month view. It is not the most liquid share so perhaps the position would need to be offloaded in tranches. I would recommend to start offloading at around R3.50.
The 12 month low was R2.03 on the 18th of July 2008 with the high being R4.38 on the 6th of November 2007.
i had a chat with analyst at nedbank about this share and he reckons that this is a 2 year position. nothing less.
good share
i rate this share but aspen is better imo